{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/onsite-manufacture-can-accelerate-your-phase-i-small-molecule-program#webpage",
"url": "https://www.fortrea.com/insights/onsite-manufacture-can-accelerate-your-phase-i-small-molecule-program",
"name": "Onsite manufacture can accelerate your Phase I small molecule program",
"description": "This Fortrea case study explores how onsite cGMP drug manufacturing was used to accelerate Phase I small molecule programs by improving manufacturing efficiency and reducing operational delays during early clinical development. The study highlights how integrating onsite manufacturing capabilities within a clinical research unit supported faster investigational product preparation, reduced active pharmaceutical ingredient (API) requirements, and minimized drug product stability constraints associated with traditional manufacturing approaches. The case study also discusses how onsite manufacturing enabled improved flexibility in formulation adjustments, direct delivery to study participants, and streamlined coordination between manufacturing and clinical operations teams. By combining Phase I clinical trial execution with integrated cGMP pharmacy services and controlled manufacturing environments, the approach supported cost efficiency, operational agility, and accelerated progression across small molecule clinical development programs"
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Onsite manufacture can accelerate your Phase I small molecule program",
"item": "https://www.fortrea.com/insights/onsite-manufacture-can-accelerate-your-phase-i-small-molecule-program"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/onsite-manufacture-can-accelerate-your-phase-i-small-molecule-program#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/onsite-manufacture-can-accelerate-your-phase-i-small-molecule-program#webpage"
},
"headline": "Accelerating Phase I Small Molecule Programs Through Onsite Drug Manufacturing | Fortrea Case Study",
"description": "This Fortrea case study explores how onsite cGMP drug manufacturing was used to accelerate Phase I small molecule programs by improving manufacturing efficiency and reducing operational delays during early clinical development. The study highlights how integrating onsite manufacturing capabilities within a clinical research unit supported faster investigational product preparation, reduced active pharmaceutical ingredient (API) requirements, and minimized drug product stability constraints associated with traditional manufacturing approaches. The case study also discusses how onsite manufacturing enabled improved flexibility in formulation adjustments, direct delivery to study participants, and streamlined coordination between manufacturing and clinical operations teams. By combining Phase I clinical trial execution with integrated cGMP pharmacy services and controlled manufacturing environments, the approach supported cost efficiency, operational agility, and accelerated progression across small molecule clinical development programs",
"genre": "Case Study",
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-09-04",
"dateModified": "2025-09-04",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-09/onsite-manufacture-accelerate-phasei-small-molecule.pdf",
"encodingFormat": "application/pdf"
}
}
]
}